Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 93 results for bevacizumab

  1. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  2. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA709

  3. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA405

  4. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

    Technology appraisal guidance
    Last updated
    26 October 2023
    View recommendations

    Sections for TA274

  5. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA305

  6. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  7. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA409

  8. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA672

  9. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    TA263/1 Question Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on...

    Research recommendation
    Published
    9 June 2015

  11. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA628

  13. Colorectal cancer (NG151)

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).

    NICE guideline
    Last updated
    15 December 2021
    View recommendations

    Sections for NG151

  14. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior...

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be...

    Research recommendation
    Published
    9 June 2015